First Health 2.0 Europe Conference to be Held in Paris

Health 2.0 Europe, a conference dedicated to how Web 2.0 and social media are transforming healthcare systems in Europe, will be held, for the first time, on April 6-7, 2010 at the Cité Universitaire International in Paris, France. Organized by e-health specialists Health 2.0 of San Francisco and Basil Strategies of Paris, the two-day event will assemble attendees from the converging industries of healthcare, the internet, mobile applications and social media, to network and brainstorm about technologies that are revolutionizing healthcare delivery and treatment.

Health 2.0 Europe's conference agenda will address a number of topics relevant to Europe's growing e-health industry. These include patients using web based tools to guide their own care, web interaction between healthcare professionals and between professionals and patients, and the strategic implications for traditional healthcare actors. The conference will also showcase innovative, European e-health start-ups and provide a platform for national healthcare leaders to address e-health issues on a European scale. Keynote speakers are senior health policy makers Etienne Caniard (French National Authority for Health) and Pieter Vos, Raad voor de Volksgezondheid en Zorg (Council for Public Health and Health Care). Over 500 attendees are expected at the inaugural event, hailing from patient and physician communities, online and mobile tool providers, hospitals, insurers, pharmaceutical companies and government in 10 European countries.

"E-health is one of the most important business sectors in Europe today," said Denise Silber, president of Basil Strategies, who is organizing the Paris event with Health 2.0's founders, Matthew Holt and Indu Subaiya. "Health 2.0 Europe integrates the Web 2.0 user-generated content concept with a number of aspects of health that are fundamentally different in Europe than in the U.S. It is therefore crucial to address the local industry with local actors from European countries, and we are thrilled by the number of partners who are already enthusiastically supporting this event."

For four years, the Health 2.0 conference has been the premier bi-annual industry forum for the converging industries of Web 2.0 and social media in the U.S. Since its inception, Health 2.0 has enjoyed a strong network of supporting partners encompassing the healthcare and technology ecosystems, ranging from industrials, to organizations, to health technology innovators.

For further information and registration, please visit:
http://www.health2con.com/paris2010/

About Health 2.0 Europe
Health 2.0 Europe is the premier conference dedicated to how Web 2.0 and social media are transforming healthcare systems in Europe. The conference brings together professionals in the converging industries of healthcare, the internet, mobile applications and social media to address how Web 2.0 and mobile technologies revolutionize both healthcare delivery and treatment. Health 2.0 Europe is organized by pioneering experts from Europe and the U.S. with decades of combined experience in health- and Web- related business and consulting, Matthew Holt and Indu Subaya, founders of Health 2.0 in San Francisco, and Denise Silber, president of Basil Strategies in Paris. The conference also partners with a number of "ambassadors", specialists in the business and Please visit www.health2con.com/paris2010 for more information, or follow Health 2.0 Europe and its online communities and groups on Twitter, Linkedin and Facebook.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...